China SXT Pharmaceuticals, Inc.
SXTC
$2.61
-$0.02-0.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.54M | 1.64M | 1.74M | 1.78M | 1.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.54M | 1.64M | 1.74M | 1.78M | 1.82M |
| Cost of Revenue | 1.20M | 1.29M | 1.37M | 1.40M | 1.42M |
| Gross Profit | 334.40K | 350.90K | 367.40K | 383.90K | 400.40K |
| SG&A Expenses | 8.72M | 5.88M | 3.05M | -1.59M | -6.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.92M | 7.17M | 4.42M | -189.30K | -4.80M |
| Operating Income | -8.38M | -5.53M | -2.68M | 1.97M | 6.62M |
| Income Before Tax | -8.87M | -6.09M | -3.30M | 1.25M | 5.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.87 | -6.09 | -3.30 | 1.25 | 5.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.87M | -6.09M | -3.30M | 1.25M | 5.80M |
| EBIT | -8.38M | -5.53M | -2.68M | 1.97M | 6.62M |
| EBITDA | -8.34M | -5.47M | -2.60M | 2.09M | 6.79M |
| EPS Basic | -161.82 | -157.70 | -153.58 | -76.79 | -- |
| Normalized Basic EPS | -101.13 | -98.56 | -95.99 | -47.99 | -- |
| EPS Diluted | -161.82 | -157.70 | -153.58 | -76.79 | -- |
| Normalized Diluted EPS | -101.13 | -98.56 | -95.99 | -47.99 | -- |
| Average Basic Shares Outstanding | 1.58M | 806.10K | 32.60K | 16.30K | -- |
| Average Diluted Shares Outstanding | 1.58M | 806.10K | 32.60K | 16.30K | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |